Evidence map›Paper›PMID 39096050›Full record

ArticleScience progress

Aetiology and management of persistent withdrawal occlusion in venous ports in oncology patients.

V Maňásek, J Zapletalová, L Olosová, I Filáková, I Kociánová, K Drdová, J Škarda, V Chovanec, D Vrána

Abstract read
In one paragraph

Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

V MaňásekVascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic.ORCID 0009-0007-4699-6025
J ZapletalováVascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic.
L OlosováVascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic.
I FilákováVascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic.
I KociánováVascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic.
K DrdováVascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic.
J ŠkardaVascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic.
V ChovanecVascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic.ORCID 0000-0001-9860-3616
D VránaVascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPersistent withdrawal occlusion (PWO) is a specific catheter malfunction characterized by the inability to withdraw blood through the device. The most common cause of PWO in ports is the presence of a fibroblastic sleeve (FS). If malfunction occurs, medication can be applied incorrectly with the increased risk of complications.

methodsOne hundred seventy-seven cases of PWO in venous ports were managed. We focused on evaluating the cause of PWO, the frequency of occurrence of FS, and the options to address the malfunction. The patients underwent fluoroscopy with a contrast agent administration. Mechanical disruption (MD) with a syringe of saline using the flush method was used; in case of its failure, subsequent administration of a lock solution with taurolidine and urokinase, or low-dose thrombolysis with alteplase was indicated. Demographic data were compared with a control group.

resultsA significantly higher proportion of female patients was found in the cohort of patients with PWO (80.3% vs 66.3%,

conclusionWe created a method for resolving PWO using MD +/- application of thrombolytics with 97.4% success rate. Current evidence showed that FS is not likely to be affected by thrombolytic drugs; however, we have ascertained an effect of these drugs, proposing a hypothesis of microthrombotic events at the tip of the catheter if fibroblastic sleeve is present.

Indexed as

NeoplasmsAdultAgedCatheterization, Central VenousCatheter ObstructionCatheters, IndwellingFemaleHumansMaleMiddle Agedanticancer treatmentFibroblastic sleevepersistent withdrawal occlusionthrombolyticsvenous ports

Identifiers

PMID39096050
PMCPMC11298061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.